India · Delayed Price · Currency is INR Brawn Biotech Statistics
Total Valuation
Brawn Biotech has a market cap or net worth of INR 63.16 million. The enterprise value is 61.28 million.
| Market Cap | 63.16M |
| Enterprise Value | 61.28M |
Important Dates
The next estimated earnings date is Thursday, February 11, 2027.
| Earnings Date | Feb 11, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
Brawn Biotech has 3.00 million shares outstanding. The number of shares has increased by 11.28% in one year.
| Current Share Class | 3.00M |
| Shares Outstanding | 3.00M |
| Shares Change (YoY) | +11.28% |
| Shares Change (QoQ) | -14.96% |
| Owned by Insiders (%) | 52.63% |
| Owned by Institutions (%) | n/a |
| Float | 920,741 |
Valuation Ratios
The trailing PE ratio is 7.96.
| PE Ratio | 7.96 |
| Forward PE | n/a |
| PS Ratio | 0.35 |
| PB Ratio | 1.39 |
| P/TBV Ratio | 1.39 |
| P/FCF Ratio | 89.30 |
| P/OCF Ratio | 87.28 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 7.49 |
| EV / Sales | 0.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 86.65 |
Financial Position
The company has a current ratio of 1.19, with zero debt.
| Current Ratio | 1.19 |
| Quick Ratio | 0.50 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -85.38 |
Financial Efficiency
Return on equity (ROE) is 19.86% and return on invested capital (ROIC) is -4.67%.
| Return on Equity (ROE) | 19.86% |
| Return on Assets (ROA) | -0.59% |
| Return on Invested Capital (ROIC) | -4.67% |
| Return on Capital Employed (ROCE) | -4.33% |
| Weighted Average Cost of Capital (WACC) | 4.84% |
| Revenue Per Employee | 30.15M |
| Profits Per Employee | 1.36M |
| Employee Count | 6 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 1.77 |
Taxes
| Income Tax | -9.40M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.67% in the last 52 weeks. The beta is 0.11, so Brawn Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | +4.67% |
| 50-Day Moving Average | 23.21 |
| 200-Day Moving Average | 21.42 |
| Relative Strength Index (RSI) | 34.93 |
| Average Volume (20 Days) | 336 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Brawn Biotech had revenue of INR 180.90 million and earned 8.18 million in profits. Earnings per share was 2.64.
| Revenue | 180.90M |
| Gross Profit | 26.36M |
| Operating Income | -1.96M |
| Pretax Income | -1.22M |
| Net Income | 8.18M |
| EBITDA | -763,890 |
| EBIT | -1.96M |
| Earnings Per Share (EPS) | 2.64 |
Balance Sheet
The company has 1.87 million in cash and no debt, with a net cash position of 1.87 million or 0.62 per share.
| Cash & Cash Equivalents | 1.87M |
| Total Debt | n/a |
| Net Cash | 1.87M |
| Net Cash Per Share | 0.62 |
| Equity (Book Value) | 45.32M |
| Book Value Per Share | 17.95 |
| Working Capital | 27.73M |
Cash Flow
In the last 12 months, operating cash flow was 723,570 and capital expenditures -16,340, giving a free cash flow of 707,230.
| Operating Cash Flow | 723,570 |
| Capital Expenditures | -16,340 |
| Depreciation & Amortization | 1.20M |
| Net Borrowing | -690,000 |
| Free Cash Flow | 707,230 |
| FCF Per Share | 0.24 |
Margins
Gross margin is 14.57%, with operating and profit margins of -1.09% and 4.52%.
| Gross Margin | 14.57% |
| Operating Margin | -1.09% |
| Pretax Margin | -0.67% |
| Profit Margin | 4.52% |
| EBITDA Margin | -0.42% |
| EBIT Margin | -1.09% |
| FCF Margin | 0.39% |
Dividends & Yields
Brawn Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.28% |
| Shareholder Yield | -11.28% |
| Earnings Yield | 12.56% |
| FCF Yield | 1.12% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |